Peptide Cyclisation and Constrained Peptides

Cyclisation is one of the most common requests for custom peptide modification.

Alongside Mimotopes’ extensive range of PepSet™ Peptide Libraries, custom peptides, antibodies, and reagents, these Cyclised Peptidesoffer unique qualities not found anywhere else.

Why Cyclise a Peptide?

Long linear peptides, unrestrained, can adopt wild and unpredictable configurations. Cyclisation restrains a peptide to better mimic the structure of the protein, and increases overall stability.

Cyclised peptides are therefore often a better representative of the natural protein.

How do you Cyclise Peptides?

Typically done after the synthesis of the linear sequence, cyclisation can be performed whilst on resin or after cleavage. Some approaches, broadly, will connect side chains to each other, to the termini, or even connect the two termini, as in head-to-tail cyclisation.

For improved activity and cell penetration, a Stapled Peptide is formed by connecting distant residues with a hydrocarbon bridge. These also tend to have a better resistance to proteolysis than their linear counterparts.

When a sequence contains two or more cysteine residues, a disulphide bridge can be chemically formed to connect the side chains. Peptides with other thiol containing residues can be similarly cyclised.

Cyclised peptides

Cyclised peptides are well known for their variation in success rate and yield, often attributable to the sequence itself as well as the methods used. A peptide company with decades of experience and proven expertise will improve the odds for better yield and higher quality.

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

 useast@mimotopes.com
   uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com


UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | Covid-19 and the anti-vax movementGo to article: In this issueGo to article: ContentsGo to article: Accurate Biometrics Company InsightGo to article: Accurate BiometricsGo to article: Contract Pharmaceuticals Limited CanadaGo to article: Mettler Toledo Company InsightGo to article: Mettler ToledoGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: WipotecGo to article: PuroliteGo to article: VEGA AustraliaGo to article: Gerteis Company Insight Go to article: GerteisGo to article: CommentGo to article: US election: Trump and Biden's priorities in the Covid-19 responseGo to article: Covid-19 disruption to trials declines, but recruitment is slowGo to article: Covid-19 vaccine developments across the globeGo to article: Eli Lilly and Regeneron’s EUA bids trigger concerns over available Covid-19 dataGo to article: AstraZeneca’s quick Covid-19 vaccine trial restart splits opinionGo to article: Q&A: Atomwise’s journey from discoverer to developerGo to article: Pfeiffer VacuumGo to article: Koehler eClinicalGo to article: Phoenix Company Insight Go to article: PhoenixGo to article: In DepthGo to article: How to combat vaccine hesitancy in the age of Covid-19Go to article: How Covid-19 has put clinical research’s diversity problem in the spotlight Go to article: No need for animal testing: improving vaccine research with GenoskinGo to article: Gout: drug development for an age-old diseaseGo to article: Treating chronic primary pain in the UKGo to article: Breast cancer breakthrough: could a new therapy silence stubborn TNBC?Go to article: Is quantum computing pharma's next big disruptor?Go to article: MimotopesGo to article: OptelGo to article: Solvias Company Insight Go to article: SolviasGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: In DataGo to article: Inside the dealGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: IWA Consulting Company Insight Go to article: IWA consultingGo to article: Nipro pharmapackagingGo to article: SwiftpakGo to article: EventsGo to article: Next issue